outperform
reason report
lower outlook base eu impass stock fulli valu
d/g mp
bottom line downgrad vertex pharmaceut
market perform outperform top
recommend appreci sinc januari
last month last
three month see stock recent strength consist
posit view reflect realist
valu compani identifi product opportun cystic
fibrosi cf reason downgrad slower
ramp compani cf product europ continu
resist payer alreadi high expect price
stock evid consensu forecast
limit near-term opportun catalyst compani
pipelin compani continu stand-off govern
payer europ particularli uk franc
elig cf patient suggest futur revenu ramp
slower lower previous forecast
reason reduc revenu forecast
year also updat compani model
vertex includ revenu contribut emerg
program antitrypsin defici aatd probability-
adjust contribut revenu program
repres valuat highlight challeng
build new opportun top compani remark
cf portfolio revis revenu forecast compani
lower consensu lower consensu
revis price target main risk
downgrad compani abl convert
european market pay custom near futur price
commensur achiev alreadi orkambi
market germani vertex becom target
 specul activ addit risk vertex
earli stage develop program pain beta thalassemia sickl
cell diseas aatd becom meaning catalyst valu
interest investor
average ep revenu multipl
dcf wacc tg
net debt total capit
price-to-earnings lt ep growth
year price history/av daili volume mil
compani inform svb leerink llc research
revenu million ep dilut exclud option expens
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
new price target vertex rate stock market perform vertex
clear clinic develop hurdl introduc medicin treat
patient cystic fibrosi cf believ market fairli valu vertex cf
portfolio loss exclus vertex launch success iter cf
medicin cloud disput price access delay reimburs
europ result success reduct revenu forecast compani
expect vertex cf revenu line grow steadili
consensu expect still robust perform compar
consensu expect believ vertex geograph revenu mix continu
heavili weight us due continu resist payer
europ dynam put current consensu mid-term revenu estim risk
probabl success tripl combin valuat account
full expect valu cf portfolio well risk-adjust opportun compani
effort antitrypsin defici aatd even posit view new dcf
valuat incorpor sustain oper margin
requir consider disciplin compani reput frugal
incorpor premium price target recogn vertex
might one attract larg cap growth asset sector howev view
reason acquisit premium would put compani cost nearli like
difficult pill swallow dilution-avers larg compani
downgrad vertex base reduct revenu forecast
compani foundat cystic fibrosi cf product europ given continu
resist payer also consid alreadi high expect price
stock evid consensu forecast limit potenti see today
reduc revenu forecast vertex later
year reduct revenu primarili slower revenu growth ex-u market
continu reimburs impass franc uk slower commerci uptak
germani last much longer anticip show sign resolut
geograph distribut cf gene franc uk repres
address market vertex cf medicin intransig payer becom
meaning headwind compani revenu perform
seem like view reimburs improv approv symdeko
therefor obviou expect reimburs least
reason price vertex tripl combin approv geographi
vertex also face risk price us could come pressur payer
hitherto capitul compani price demand concess return yet anoth
expand patient popul tripl
european revenu remain slow prior expect
vertex report total cf product sale us
ex-u market sale mainli europ half revenu
europ came kalydeco wide reimburs adopt us
ex-u market wherea revenu us came kalydeco kalydeco
contribut declin rel basi given approxim even distribut patient
us ex-u market would normal expect revenu ratio
singl drug doublet ultim triplet therapi similar us ex-u
market kalydeco us ou stage vertex doublet revenu us
five-fold higher ex-u market major limit adopt orkambi
symdeko/symkevi outsid us reimburs sever larg countri uk
franc impass vertex price countri extract major discount
compar expect price australia ireland netherland countri
restrict adopt germani even countri provid access realiz
price major discount us price calcul penetr orkambi
symkevi ex-u reach exit compar us
practic result slower adopt previous forecast lower price
realiz well thu accentu shortfal expect sale outsid us
shortfal assum becom less perman result lower
penetr lower price vertex cf regimen market outsid us
previous forecast rapid acceler cf revenu ex-u market reach
vertex actual realiz total cf sale
ex-u market recent ex-u revenu forecast compani seem
increasingli unachiev compar forecast vertex realiz cf sale
lower shortfal come us ex-u market still
forecast rapid ramp sale us ex-u market prior forecast doubl
sale increas given continu stand-off
payer franc uk lower price market agre
reimburs believ revenu fall short estim ex-u market
adjust forecast model valuat accordingli
lower revenu forecast vertex cf portfolio ex-u market
long-term forecast compani
cf product ex-u market reduc reduc total revenu forecast
later year reduc
expens forecast modestli parallel reduc revenu forecast oper
margin outlook alreadi aggress oper margin increas
year long-term oper margin trend
consist highest oper margin observ industri even
highli profit rare diseas product practic impli vertex keep virtual
flat compar estim sg expens trend
increas consist
compani increas commerci support multipl cf product well increas cost
free good allow market expand histor vertex given indic
destin industry-lead profit respect forecast may
chang adjust revenu forecast vertex recent consensu
longer term adjust forecast current
consensu adjust ep estim lower prior estim
lower later year new ep estim incorpor
slower expens growth current consensu year
vertex global price power cf portfolio declin
vertex origin abl secur global reimburs first cf medicin kalydeco
price us alway paid highest price kalydeco list
european govern receiv discount base price report
govern local patient advocaci group media howev compani abil win
global reimburs price assist rel small patient popul
cf patient origin indic kalydeco small popul put less strain
healthcar budget european countri subsequ label expans kalydeco
launch orkambi symdeko expand treatabl patient popul
us vertex price new medicin discount kalydeco
uptak robust compani requir negoti substanti discount
outsid us receiv reimburs exampl price germani orkambi
wide cite discount us price sever countri includ ireland
canada england initi reject price offer orkambi vertex includ
discount
vertex respond price struggl orkambi outsid unit state negoti
secur cap portfolio deal certain countri withhold product
countri portfolio deal gave access vertex current medicin includ orkambi
kalydeco well yet approv price nation pay confidenti
deal typic includ set price per patient annual total payment cap result
certain volum threshold cross patient receiv vertex medicin
lower price patient put downward pressur averag global price
treat popul increas type deal agre far ireland
australia sweden denmark exhibit
exhibit exampl published/report list price vertex cf medicin
reimburs struggl outsid unit state best exemplifi on-going multi-
year negoti england price orkambi futur cf medicin england one
import market vertex given high preval cf countri uk
regist cf patient world cf popul despit
world popul drug approv england must receiv reimburs
negoti price nation health servic nh receiv advic nation
institut excel whether new medicin cost effect
england current pay year kalydeco base agre price
per patient nh expect renegoti lower amount
period despit three year negoti nh vertex agre price
orkambi origin propos vertex per patient per year orkambi
small discount price discuss germani though offer lowest
publish list price orkambi world nh deem far excess cost
effect nh reject vertex offer instead counter-off capit payment
year year vertex approv cf medicin mani patient
elig so-cal model essenti would amount england pay
per patient per year discount lowest known price vertex turn
offer juli say inadequ unfair compani also
withdrawn newer effect drug symkevi england reimburs process
mean avail nh patient vertex ceo dr jeffrey leiden
current on-going late-stag negoti directli england secretari state
social dr leiden also testifi march england health social
committe price vertex cf medicin question intent
grow profit compani execut compens plan role research
grant invent vertex cf medicin none testimoni comment
question suggest compromis immin price anywher near
achiev us even european market germani
us -- kalydeco orkambi cad ireland orkambi orkambi portfolio dealsireland australia sweden denmarkglob price exampl vertex cf medicin vertex incorpor
franc countri develop world cf popul countri
patient elig orkambi/symdeko also push back price vertex cf
medicin countri oper earli access program pay drug invoic
price formal reimburs decis negoti vertex collect
franc orkambi procedur book earli access sale accrual
vertex balanc sheet formal reimburs negoti broken
unclear much vertex requir pay back franc initi propos
orkambi price benchmark pulmozym protein therapi enhanc lung
clearanc cost per year respons stall negoti vertex
cancel plan host clinic trial site tripl therapi franc seem
like vertex introduc symkevi franc either situat suggest
revenu market default intern market continu lag behind
forecast also street expect bode well adopt tripl
combin despit remark efficaci
lower rel price vertex medicin ex-u countri lack patient access
market england franc concentr vertex cf revenu us us
account known global cf patient popul yet repres vertex cf
revenu sinc launch orkambi revenu contribut us
grown exhibit revenu remain concentr us like
vertex would fall short forecast consensu current model forecast ex-
us revenu mix grow avail consensu revenu
sourc vertex also requir ex-u revenu mix grow
us proport revenu
furthermor geograph revenu imbal could heighten price pressur
begin emerg us vertex price situat patient access rel
superior unit state patient treatment data unit state cystic fibrosi
foundat suggest net realiz price per patient significantli lower list price
orkambi registri list patient kalydeco patient orkambi
kalydeco orkambi achiev fourth quarter us revenu
respect annual basi result suggest net price year
kalydeco orkambi kalydeco realiz price
discount form list orkambi realiz price discount list exhibit
discount orkambi consist prior year calcul realiz price
use foundat data lower realiz price orkambi partial attribut
liabil drug high rate discontinu plausibl
improv profil symdeko command higher net price although still like
substanti discount compar kalydeco model tripl achiev us net price
may risk haircut depend appetit payer
cover even larger number cf patient expand label tripl
exhibit estim realiz us price per patient vertex cf medicin
divid
number patient
consensu alreadi incorpor near perfect penetr cf popul
vertex one rare larg cap biotech stock experienc increas long-term
revenu expect past two year sale expect compani
jump releas phase data tripl combin
forecast continu increas next sever quarter present
vertex stock perform correl close increas estim exhibit
current estim global revenu per patient peak penetr translat
penetr patient expect global cf patient popul
exhibit trajectori vertex consensu revenu estim
howev vertex histori miss high expect consensu tend
model rampant march peak patient penetr leav littl room commerci
execut error delay reimburs exampl estim vertex revenu
grew releas orkambi phase result estim
began drift downward drug launch physician feedback drug intoler
materi proport patient factor market ultim miss quarterli
result revenu warn comment compani cfo sent estim roughli
lower month late start concurr stock lost
approxim valu august begin even launch
symdeko elimin toler issu increas efficaci rel
orkambi estim increas modestli total
actual report revenu result lower consensu expect
approxim correct initi apprais futur valu base phase result
high howev releas tripl therapi data subsequ spike
revenu estim turn stock around earli exhibit
exhibit trajectori vertex consensu revenu estim
high consensu estim requir signific increment growth vertex
sale guidanc assum kalydeco revenu remain constant vertex
need add sale tripl regimen year top sold today
amount increas cf combin patient revenu
compound-annual-growth-rate assum averag global price per
patient increment revenu would requir treatment new
homozyg het/min patient doubl tripl combin
homozyg het/min popul increas would bring total homozyg
het/min treatment penetr exhibit global price per patient fall
vertex would need achiev penetr reach consensu estim
posit side increas penetr kalydeco expand label
popul may provid addit revenu lower patient penetr requir
combin therapi meet consensu howev decreas averag price per patient
compar expect would requir even higher treatment penetr
exhibit estim global patient penetr need reach consensu
abil vertex achiev high penetr within three year tripl combin
launch guarante achiev would requir success approv
tripl europ also widespread reimburs treatment recommend
seen countri total treatabl cf popul refus pay
vertex price medicin treat much smaller popul address
forthcom tripl combin countri bargain cap maximum annual
payment vertex regardless number patient treat far least appear
success combin reimburs adopt unit state accord
cf foundat cff patient registri orkambi alreadi use patient
meet label indic three year sinc product launch exhibit
penetr rate outsid us less well document vertex us vs ex-u
revenu split doublet combin suggest penetr still dramat lower ex-
us market estim correspond doublet penetr ex-u elig patient
rang given report sale current label market vertex
report franc patient elig orkambi therapi uniqu
countri patient continu treat unrestrict temporari
reimburs program compani attempt negoti final reimburs price
cf revenu revenu assum combin non-kalydeco revenu assum kalydeco revenu constant cf combin revenu need increas cf combin revenu guidanc increas compound-annual-growth-rate patient need treat assum global global homozyg min patient treat penetr homozyg min patient meet revenu vertex incorpor
exhibit cff us orkambi penetr data lung function
may argu orkambi good compar potenti futur treatment
penetr drug lower efficaci compar kalydeco toler
issu howev kalydeco penetr expand label popul also
small initi patient popul similar
current orkambi penetr rate homozyg exhibit believ real
risk launch adopt tripl also lag consensu expect particularli ex-
us market ultim adopt could still fall significantli impress
adopt kalydeco origin indic
exhibit cff us kalydeco penetr data year
could anoth vertex pipelin ad aatd model
recent preview vertex potenti opportun small molecul corrector treat
antitrypsin defici aatd posit vertex therapeut approach
preclin data concern size commerci opportun due low
rate diagnosi aatd today rel benign diseas outlook affect
patient stand believ aatd revenu opportun would rel small
fraction compar peak sale estim vertex cf portfolio see note
scout report aatd enough give anoth
built initi aatd market model ad probabl adjust revenu
indic vertex compani model assum popul patient split evenli
us estim diagnos proport patient increas
level today slightli introduct effect therapi
current standard augment use less patient today
current four compani market augment pulmonologist
hepatologist point basi suggest under-diagnosi
significantli alter new aatd corrector treatment assum vertex corrector launch
price us eu signific
premium averag current price augment assum vertex treatment
offer greater conveni superior diseas modif compar current
augment achiev penetr diagnos treat patient popul
period estim peak penetr roughli lower eu
given price sensit market heterogen diseas present
identif progress ultim sever price sensit european market believ
use like restrict sever patient
unadjust us forecast grow
peak ex-u forecast grow
peak combin estim global sale grow
peak probability-adjust revenu given product stage
develop thu global revenu reduc exhibit
exhibit svb leerink forecast risk-adjust sale vertex aatd program
sensit analysi cf revenu outcom suggest offer materi
given consensu estim appear reflect high penetr cystic fibrosi
opportun possibl valu program rel high degre certainti two
variabl price per patient time
expect realiz price materi variabl determin valu cf portfolio
today vertex list price per patient per year unit state
compani price negoti us almost discount
europ entir countri refus pay vertex ask price see section
averag global price per patient could vari significantli futur vertex maintain
monopoli posit cf indic expand indic popul address
theoret maximum cystic fibrosi popul would expect realiz price
fall somewher actual price realiz conting
unknown list price decis vertex tripl therapi us negoti
countri outsid unit state either tripl full portfolio price
second import variabl initi year valuat analysi cf portfolio
growth asset improv profit continu next sever year
year pass reduc time discount appli higher futur cash flow
increas valu portfolio vertex stock least cash flow growth off-set
one year less cash flow
two variabl mind creat sensit analysi valu vertex
cf portfolio compar vertex current market capit share price
exhibit complet two differ analys multipl price time
scenario analysi first analysi stand-alone compani model reach peak
oper margin continu invest heavili approxim per year
sinc idea invest product might emerg
assign stock valu expens henc repres minimum valu second
 model vertex portfolio could worth acquir could strip expens
run portfolio oper margin henc maximum valu essenti
calcul exit price cf portfolio arms-length transact
scenario model current consensu revenu forecast year
continu grow revenu peak penetr address cf
patient current grow annual line growth
cff patient registri flatten cash flow expect patent expir
cf portfolio global price per patient scenario analyz
assumpt gener peak global
sale cf portfolio assum tax rate
begin compani stand-alone entiti tax rate assum
synergi acquir model discount cash flow scenario
vertex wacc add cash expect vertex carri
end calcul valu per share scenario run dcf analysi
start gaug potenti increas valu cf
portfolio increment buyer due time valu money divid net present
valu dilut share outstand calcul valu vertex cf portfolio
comparison current stock price
result suggest vertex current stock price alreadi valu cf portfolio
almost price time scenario least stand-alone entiti continu invest
 lower averag global revenue/pati scenario valu
cf portfolio current stock price mean vertex current stock
price must attribut compani non-cf program moreov addit
program would need increas valu worth total
valu cf program per analysi stock offer upsid current trade
level vertex would need achiev consider return scenario annual
 expens achiev pipelin valuat
addit public trade non-commerci biotech stock valu
offer compar addit requir valu conclus portion
analysi vertex current stock price alreadi fulli valu cf portfolio
realist price profit scenario alreadi bake signific valu pipelin
futur unalloc invest investor would expect pipelin would
gener valu level offer upsid stock recent level
scenario analysi support valu came adjust free stand compani
model lower revenu slower european sale lower ex-u price also
consist view upsid stock recent level requir huge confid
compani pipelin alreadi price stock initi analysi
suggest pipelin promis earli stage opportun offer billion
valu continu recommend stock rang
stock look margin attract synergi scenario
assumpt global price per patient impli upsid stock current price
howev year reach price per patient reach
upsid exce acquir could continu invest vertex aatd pain asset
extract valu acquisit potenti opportun rel modest
comparison peak cf revenu scenario analysi believ
potenti acquir would conduct similar analysi cf portfolio could easili conclud
offer price accept vertex manag board sharehold like well
would rel low probabl gener posit return
reason cost capit major risk market perform thesi potenti acquisit
vertex analysi suggest premium requir top current stock price would
make deal prohibit expens acquir given peak potenti cf portfolio
tangibl valu non-cf program earli stage develop
exhibit vertex cf portfolio valuat two variabl drug price dcf year
assumpt address patient treatment penetr cliff end margin margin stand-alone rate rate stand-alone end stand-alone per stock year dcfiniti year dcfvalu per dilut share outvalu per dilut share price per patientglob price per patient vertex incorpor
price target vertex base simpl averag three approach
believ reason basi valu stock today approach simpl price
earn multipl higher growth larg cap biopharmaceut compani price sale
multipl mid larg cap high growth biopharmaceut compani discount cash
flow dcf use current averag high growth larg cap biopharma multipl ep
nvo azn appli current ep estim
discount back year compani cost equiti give valu one
year use averag high growth larg cap biotech price-to-revenu multipl sale
nvo appli revenu estim
post-tripl discount back year compani cost
equiti give valu one year lastli dcf valuat given wacc
termin cash flow growth rate give present valu averag three
method current price target
risk view outlook valuat vertex includ major chang price
reimburs coverag label competit posit kalydeco orkambi symdeko
compani main product today major risk disappoint delay failur
compani develop regulatori file novel tripl combin medicin
cystic fibrosi risk includ continu lack access reimburs vertex
medicin acceler success develop altern modul cftr
altern approach treat cf gene therapi final compani histori
spend much potenti earn expens diversifi acquisit could undermin
futur expect valu compani cf portfolio opportun better-than expect
perform includ realiz signific revenu compani current cf dual
combin market outsid us well acceler clinic develop regulatori
approv reimburs tripl combin regimen
svb leerink research compani file zack factset consensu
svb leerink research compani file zack factset consensu
brand
type event
event trial detail
date known
up/down
expect
phase iib dose rang studi patient
nda file cf patient year old
fda approv cf patient year old
svb leerink llc research compani file
million
product sale po adjust
tripl combin kalydeco second corrector full year sale
total product sale book
product sale po adjust
total product sale book
svb leerink llc research compani file
million
product sale direct product sale vertex
sale
forma tax excl nol benefit cash
 total revenu
sg total revenu
tax rate note differ pro forma due nol benefit cash
svb leerink llc partner research compani file
analysi stock price svb leerink target
method higher growth large-cap healthcar ep multipl svb leerink normal
current averag growth larg cap biopharma multipl ep nvo azn
svb leerink ep
impli price ep use current consensu high growth larg cap multipl
equiti
number period
impli one year target price approach
method discount futur valu normal revenu use mid larg cap biotech compar
averag growth larg cap mid cap biotech price-to-revenu multipl sale
impli vertex enterpris valu sale estimate mm
estimate net
impli vertex equiti valu mm
equiti
number period
impli vertex valu mm
impli one year target price approach
method dcf base current product po adjust outlook cf franchis use wacc
present valu late stage market product flow
net debt end
averag method
svb leerink llc research compani file factset
